• 1. Single-molecule protein sensing in a nanopore: a tutorial
  Nitinun Varongchayakul,Jiaxi Song,Amit Meller,Mark W. Grinstaff Chem. Soc. Rev. 2018 47 8512
• 2. Interrelationships between the tetrahedral and planar polymorphs of bis(3-ethylamino-1-phenyl-but-2-en-1-ono)nickel(ii) and structural comparisons with related CoII, NiII, CuII, and ZnII complexes
  Xian B. Powers,Kamran B. Ghiassi,Joshua T. Greenfield,Marilyn M. Olmstead,Alan L. Balch CrystEngComm 2017 19 3244
• 3. Pharmacological and therapeutic properties of new derivatives of renin inhibitors and endothelin receptor antagonists, and the methods of their determination
  Mariusz Stolarczyk,Anna Apola,Anna Ma?lanka,Jan Krzek Anal. Methods 2015 7 4419
• 4. Quantum spin liquid: design of a quantum spin liquid next to a superconducting state based on a dimer-type ET Mott insulator
  Takaaki Hiramatsu,Yukihiro Yoshida,Gunzi Saito,Akihiro Otsuka,Hideki Yamochi,Mitsuhiko Maesato,Yasuhiro Shimizu,Hiroshi Ito,Hideo Kishida J. Mater. Chem. C 2015 3 1378
• 5. Structural, spectroscopic and redox properties of uranyl complexes with a maleonitrile containing ligand
  Helen C. Hardwick,Drew S. Royal,Madeleine Helliwell,Simon J. A. Pope,Lorna Ashton,Roy Goodacre,Clint A. Sharrad Dalton Trans. 2011 40 5939

Endothelin-2 (49-69), Human: A Comprehensive Overview of CAS No. 123562-20-9

Endothelin-2 (49-69), human, identified by the CAS number CAS No. 123562-20-9, is a critical peptide hormone that plays a pivotal role in the regulation of vascular tone, blood pressure, and tissue homeostasis. This compound is a naturally occurring member of the endothelin family, which consists of three structurally related peptides: endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3). Each of these peptides exerts distinct physiological and pathophysiological effects, with ET-2 being particularly noted for its potent vasoconstrictive properties and involvement in various cellular processes.

The structure of Endothelin-2 (49-69), human, consists of 21 amino acids arranged in a specific sequence that determines its biological activity. The peptide is synthesized in vascular endothelial cells and smooth muscle cells through the action of endothelin-converting enzymes, specifically endothelin-converting enzyme 1 (ECE-1) and endothelin-converting enzyme 2 (ECE-2). Once released, ET-2 binds to two distinct G-protein coupled receptors: ETA and ETB. The ETA receptor is primarily responsible for mediating vasoconstriction, while the ETB receptor can both mediate vasoconstriction and promote vasodilation through the release of nitric oxide.

Recent research has highlighted the significant role of Endothelin-2 (49-69), human, in various physiological and pathological conditions. Studies have demonstrated that ET-2 contributes to the regulation of blood pressure by inducing vasoconstriction in the systemic circulation. Additionally, it has been implicated in the pathogenesis of cardiovascular diseases, such as hypertension, atherosclerosis, and heart failure. The potent vasoconstrictive effects of ET-2 make it a key player in maintaining vascular tone and responding to physiological stressors.

In terms of therapeutic applications, Endothelin-2 (49-69), human, has garnered attention as a potential biomarker and therapeutic target for managing cardiovascular disorders. Researchers have explored the use of ET receptor antagonists to mitigate the adverse effects associated with excessive ET signaling. These antagonists, such as bosentan and ambrisentan, have shown promise in clinical trials for conditions like pulmonary arterial hypertension (PAH) and chronic heart failure. The development of selective ETA receptor antagonists has been particularly promising, as they can block vasoconstriction without affecting other physiological processes mediated by ETB receptors.

The synthesis and purification of Endothelin-2 (49-69), human, are critical for both research and therapeutic purposes. High-performance liquid chromatography (HPLC) and mass spectrometry techniques are commonly employed to ensure the purity and integrity of the peptide. Advances in synthetic biology have also enabled the production of recombinant ET-2 using bacterial or mammalian cell systems, providing researchers with a reliable source for experimental studies.

Endothelin-2 (49-69), human, has also been studied for its role in inflammation and tissue repair. Emerging evidence suggests that ET-2 can modulate immune responses by interacting with various inflammatory mediators. This interaction may contribute to its involvement in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Furthermore, ET-2 has been observed to promote fibroblast proliferation and collagen production, which are essential processes in wound healing but can also lead to fibrosis if dysregulated.

The pharmacological manipulation of ET signaling has opened new avenues for treating neurological disorders as well. Studies have indicated that ET-2 may play a role in neuroprotection against ischemic damage by activating specific signaling pathways that enhance neuronal survival. This finding has sparked interest in developing drugs that can leverage ET receptors to protect against brain injury following stroke or traumatic brain injury.

Future research directions for Endothelin-2 (49-69), human, include exploring its role in metabolic diseases such as obesity and diabetes. Preliminary studies have suggested that ET-2 may influence glucose metabolism by affecting insulin sensitivity in adipose tissue. Understanding these mechanisms could lead to novel therapeutic strategies for managing metabolic syndrome.

In conclusion, Endothelin-2 (49-69), human, is a multifaceted peptide with significant implications for both physiology and pathology. Its potent vasoconstrictive effects make it a key regulator of cardiovascular function, while its involvement in inflammation and tissue repair highlights its broader biological significance. The ongoing research into ET signaling pathways continues to uncover new therapeutic opportunities across multiple disease areas.

• 58-49-1(Angiotensin II 5-valine)
• 117399-94-7(Endothelin 1 (swine, human))
• 50-57-7(Lysipressin)
• 1407-47-2(Angiotensin)
• 121695-87-2(Sarafotoxin S 6c (9CI))
• 1405-87-4(Bacitracin)
• 5534-95-2(Pentagastrin)
• 9034-50-8(Vasotocin)
• 117399-93-6(Endothelin 3 (human)(9CI))
• 50-56-6(Oxytocin)